Voluntary nationwide recall: Prograf and Astagraf (Astellas – December)

Jan. 2025Pharmacy Updates

Astellas Pharma US, Inc. is recalling one lot of Prograf, lot 0E3353D, and one lot of Astagraf XL, lot 0R3092A. Prograf and Astagraf XL are used in conjunction with other medicines to help prevent organ transplant rejection.

These drugs are being recalled because bottles may contain empty capsules. Using empty capsules may result in organ transplant rejection that may be fatal.

To see if your medication was recalled, contact your doctor or pharmacy where you received it or visit the FDA website below. If you have an affected lot of Prograf or Astagraf XL, you should stop using the product and contact your pharmacy where you received it for a replacement.

As of Dec. 26, there had been no reports of adverse events related to this recall.

To learn more about this recall, you can take one or more of the steps below.

  • Talk to your doctor or pharmacist.
  • Call Astellas Medical Information at 1-800-727-7003. TTY users should call 711. Help is available Monday through Friday from 9 a.m. to 5:30 p.m. EST.
  • Visit the FDA website.

Recent Announcements

Important announcement – Telehealth submissions

As of October 1, 2025, UPMC Health Plan continues to accept the submission of telehealth claims. Providers may conduct telehealth visits for UPMC Health Plan members in all UPMC Insurance products. UPMC Insurance products include UPMC Advantage group and individual products, UPMC for Life Medicare Advantage plans, UPMC for Kids CHIP plans, UPMC Community HealthChoices, and UPMC for You Medical Assistance plans.
Sep. 2025Important Notices

October 2025 UPMC for You and UPMC Community HealthChoices Formulary Update

Effective October 1st, 2025, Xifaxan and Retin-A (cream, gel) will no longer be covered by UPMC for You and UPMC Community HealthChoices due to non-participation in the Medicaid Drug Rebate Program.
Sep. 2025Pharmacy Updates

Biosimilar Medication Formulary Updates

Updates to formulary biosimilar medications for denosumab, eculizumab, and ustekinumab products
Sep. 2025Pharmacy Updates